Cargando…

Safety of Aflibercept in Metastatic Colorectal Cancer: A Literature Review and Expert Perspective on Clinical and Real-World Data

Background: Metastatic colorectal cancer (mCRC) represents a substantial health burden globally and an increasing challenge in Asian countries. Treatment options include chemotherapy plus a vascular endothelial growth factor (VEGF) inhibitor (such as bevacizumab, aflibercept or ramucirumab), or anti...

Descripción completa

Detalles Bibliográficos
Autores principales: Muro, Kei, Salinardi, Taylor, Singh, Arvind Rup, Macarulla, Teresa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7225956/
https://www.ncbi.nlm.nih.gov/pubmed/32244546
http://dx.doi.org/10.3390/cancers12040844
_version_ 1783534174287691776
author Muro, Kei
Salinardi, Taylor
Singh, Arvind Rup
Macarulla, Teresa
author_facet Muro, Kei
Salinardi, Taylor
Singh, Arvind Rup
Macarulla, Teresa
author_sort Muro, Kei
collection PubMed
description Background: Metastatic colorectal cancer (mCRC) represents a substantial health burden globally and an increasing challenge in Asian countries. Treatment options include chemotherapy plus a vascular endothelial growth factor (VEGF) inhibitor (such as bevacizumab, aflibercept or ramucirumab), or anti-epidermal growth factor receptor (EGFR) therapies. Aflibercept, a recombinant fusion protein, has been approved for treatment of mCRC in combination with FOLFIRI for patients whose disease progresses during or after treatment with an oxaliplatin-containing regimen, based on its efficacy and tolerability profile in clinical trials. This report aims to provide an overview of both clinical and real-world evidence and experience on the use of aflibercept in routine clinical practice, with a focus on European, American and Asian populations. Methods: A literature search was conducted in PubMed (on 28th February 2019) using the search terms ("aflibercept") and ("Colorectal"OR"CRC") to identify publications containing information on aflibercept-containing regimens. Results: The adverse events (AE) profile was similar between geographical locations. Across trials, real-world and retrospective studies, grade ≥ 3 hypertension and proteinuria were amongst the most frequently reported AEs. Conclusions: The safety profile of aflibercept is generally manageable and comparable across various geographic locations.
format Online
Article
Text
id pubmed-7225956
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-72259562020-05-18 Safety of Aflibercept in Metastatic Colorectal Cancer: A Literature Review and Expert Perspective on Clinical and Real-World Data Muro, Kei Salinardi, Taylor Singh, Arvind Rup Macarulla, Teresa Cancers (Basel) Review Background: Metastatic colorectal cancer (mCRC) represents a substantial health burden globally and an increasing challenge in Asian countries. Treatment options include chemotherapy plus a vascular endothelial growth factor (VEGF) inhibitor (such as bevacizumab, aflibercept or ramucirumab), or anti-epidermal growth factor receptor (EGFR) therapies. Aflibercept, a recombinant fusion protein, has been approved for treatment of mCRC in combination with FOLFIRI for patients whose disease progresses during or after treatment with an oxaliplatin-containing regimen, based on its efficacy and tolerability profile in clinical trials. This report aims to provide an overview of both clinical and real-world evidence and experience on the use of aflibercept in routine clinical practice, with a focus on European, American and Asian populations. Methods: A literature search was conducted in PubMed (on 28th February 2019) using the search terms ("aflibercept") and ("Colorectal"OR"CRC") to identify publications containing information on aflibercept-containing regimens. Results: The adverse events (AE) profile was similar between geographical locations. Across trials, real-world and retrospective studies, grade ≥ 3 hypertension and proteinuria were amongst the most frequently reported AEs. Conclusions: The safety profile of aflibercept is generally manageable and comparable across various geographic locations. MDPI 2020-03-31 /pmc/articles/PMC7225956/ /pubmed/32244546 http://dx.doi.org/10.3390/cancers12040844 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Muro, Kei
Salinardi, Taylor
Singh, Arvind Rup
Macarulla, Teresa
Safety of Aflibercept in Metastatic Colorectal Cancer: A Literature Review and Expert Perspective on Clinical and Real-World Data
title Safety of Aflibercept in Metastatic Colorectal Cancer: A Literature Review and Expert Perspective on Clinical and Real-World Data
title_full Safety of Aflibercept in Metastatic Colorectal Cancer: A Literature Review and Expert Perspective on Clinical and Real-World Data
title_fullStr Safety of Aflibercept in Metastatic Colorectal Cancer: A Literature Review and Expert Perspective on Clinical and Real-World Data
title_full_unstemmed Safety of Aflibercept in Metastatic Colorectal Cancer: A Literature Review and Expert Perspective on Clinical and Real-World Data
title_short Safety of Aflibercept in Metastatic Colorectal Cancer: A Literature Review and Expert Perspective on Clinical and Real-World Data
title_sort safety of aflibercept in metastatic colorectal cancer: a literature review and expert perspective on clinical and real-world data
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7225956/
https://www.ncbi.nlm.nih.gov/pubmed/32244546
http://dx.doi.org/10.3390/cancers12040844
work_keys_str_mv AT murokei safetyofafliberceptinmetastaticcolorectalcanceraliteraturereviewandexpertperspectiveonclinicalandrealworlddata
AT salinarditaylor safetyofafliberceptinmetastaticcolorectalcanceraliteraturereviewandexpertperspectiveonclinicalandrealworlddata
AT singharvindrup safetyofafliberceptinmetastaticcolorectalcanceraliteraturereviewandexpertperspectiveonclinicalandrealworlddata
AT macarullateresa safetyofafliberceptinmetastaticcolorectalcanceraliteraturereviewandexpertperspectiveonclinicalandrealworlddata